Skip to main content
Equibles
WVE logo

WVE · Wave Life Sciences, Inc. · Metrics

Track WVE — free

Use WVE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research WVE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.13 -0.03 (-0.79%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$617.33M
Shares
197.23M
Volume · Nov 13 2.66M Avg daily vol (3M) 3.16M

WVE metrics

78 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.13
Market cap
$617.33M

Price action

23 metrics
Price change (1W)
-7.0%
Price change (30D)
-1.9%
Price change (3M)
-42.1%
Price change (6M)
-53.8%
Price change (YTD)
-81.6%
Price change (1Y)
-53.1%
Trailing year
Price change (5Y)
-32.8%
52-week high
$21.31
52-week low
$3.09
Change from 52-week high
-85.3%
Change from 52-week low
+1.3%
Annualized volatility
167.8%
Annualized volatility (3M)
56.5%
Implied volatility (30D)
147.5%
IV rank (1Y)
63.5
IV percentile (1Y)
91.8
Beta
1.4
RSI (14D)
37.7
Price vs SMA 50
-16.1%
Price vs SMA 200
-54.8%
Avg volume (3M)
3.16M
Relative volume
0.8
Average dollar volume
$12.86M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
197.23M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
2.6×
reciprocal yield 38.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
8.7×
reciprocal yield 11.5%
P / book
1.5
reciprocal yield 65.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-34.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
10.2×
reciprocal yield 9.8%
EV / revenue historical average (5Y)
10.2×
reciprocal yield 9.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-27

Profitability

9 metrics
Gross margin
—
Operating margin
-320.9%
Trailing 12 months
Net margin
-296.9%
Gross profit (TTM)
—
Operating profit (TTM)
−$227.61M
Net income (TTM)
−$210.53M
Trailing 12 months
Diluted EPS (TTM)
$-1.06
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.36
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.16
EBITDA per diluted share (TTM)
$-2.37
Net income per diluted share (TTM)
$-1.07
Operating cash flow per diluted share (TTM)
$-1.04
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.05
Stock compensation per diluted share (TTM)
—
Book value per share
$1.37

Growth

11 metrics
Revenue growth YoY
+72.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$70.92M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+21.7%
Year over year · more shares
Revenue CAGR (3Y)
+127.1%
Revenue CAGR (5Y)
+16.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-52.4%
Return on assets
-41.4%
Debt / equity
0.0
Current ratio
8.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
8.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$430.75M
Latest balance sheet
Cash & equivalents
$197.31M
Total assets
$507.93M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$207.05M
Capital expenditures (TTM)
$1.34M
R&D (TTM)
$205.39M
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
289.6%
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
239
13F filer change QoQ
+7
Institutional ownership
92.9%
Conviction holders (share of 13F filers)
2.1%
Crowding (high-turnover and private-fund holders)
48.7%
Private-fund adviser ownership
46.4%
Active holders' share change QoQ
+1.5%
Holder tenure
13.6
Price vs estimated holder cost
-26.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
2.1%

Short interest

3 metrics
Short interest
10.5%
Latest settlement · 6.8 days to cover
Days to cover
6.8d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1631574 CUSIP 94352A104 13F (30d) 161 filings 146 filers Visit website Investor relations